降压药物治疗预防心血管病与死亡的年龄及血压分层效应:个体参与者数据荟萃分析
相对风险降低在各基线血压水平间无显著异质性,绝对风险降低随年龄增长而增大。
要点
- 降压治疗至老年仍有效,相对风险降低不随基线血压水平变化。
- 绝对风险降低随年龄增长而增大,老年组获益更明显。
核心结论
- 降压药物治疗至老年仍有效,主要心血管事件相对风险降低不随基线收缩压或舒张压水平变化,低至<120/70 mmHg亦然。
- 应移除国际指南中与年龄相关的血压阈值,降压治疗应视为不分年龄的重要治疗选择。
研究设计与样本
- 比较降压药物与安慰剂或其他降压药,或强化与常规治疗策略;排除有心力衰竭史者。
- 按基线年龄(<55、55-64、65-74、75-84、≥85岁)和血压类别(收缩压每10 mmHg从<120至≥170,舒张压从<70至≥110)分层。
- 采用固定效应一阶段方法,以试验分层的Cox比例风险模型分析。
主要发现
- 每降低3 mmHg舒张压,相对风险降低模式相似。
- 各年龄组内不同基线血压类别间未发现临床有意义的相对治疗效应异质性。
临床怎么用
- 降压药物治疗应视为不分年龄的重要治疗选择,包括70岁以上及血压未显著升高者。
- 国际指南应考虑移除与年龄相关的血压阈值。
- 临床决策中需注意老年组绝对风险降低更大,但≥85岁相对风险降低证据不确定。
局限性
- 排除有心力衰竭史者,结论不适用于该人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The effects of pharmacological blood-pressure-lowering on cardiovascular outcomes in individuals aged 70 years and older, particularly when blood pressure is not substantially increased, is uncertain. We compared the effects of blood-pressure-lowering treatment on the risk of major cardiovascular events in groups of patients stratified by age and blood pressure at baseline. METHODS: We did a meta-analysis using individual participant-level data from randomised controlled trials of pharmacological blood-pressure-lowering versus placebo or other classes of blood-pressure-lowering medications, or between more versus less intensive treatment strategies, which had at least 1000 persons-years of follow-up in each treatment group. Participants with previous history of heart failure were excluded. Data were obtained from the Blood Pressure Lowering Treatment Triallists' Collaboration. We pooled the data and categorised participants into baseline age groups (<55 years, 55-64 years, 65-74 years, 75-84 years, and ≥85 years) and blood pressure categories (in 10 mm Hg increments from <120 mm Hg to ≥170 mm Hg systolic blood pressure and from <70 mm Hg to ≥110 mm Hg diastolic). We used a fixed effects one-stage approach and applied Cox proportional hazard models, stratified by trial, to analyse the data. The primary outcome was defined as either a composite of fatal or non-fatal stroke, fatal or non-fatal myocardial infarction or ischaemic heart disease, or heart failure causing death or requiring hospital admission. FINDINGS: We included data from 358 707 participants from 51 randomised clinical trials. The age of participants at randomisation ranged from 21 years to 105 years (median 65 years [IQR 59-75]), with 42 960 (12·0%) participants younger than 55 years, 128 437 (35·8%) aged 55-64 years, 128 506 (35·8%) 65-74 years, 54 016 (15·1%) 75-84 years, and 4788 (1·3%) 85 years and older. The hazard ratios for the risk of major cardiovascular events per 5 mm Hg reduction in systolic blood pressure for each age group were 0·82 (95% CI 0·76-0·88) in individuals younger than 55 years, 0·91 (0·88-0·95) in those aged 55-64 years, 0·91 (0·88-0·95) in those aged 65-74 years, 0·91 (0·87-0·96) in those aged 75-84 years, and 0·99 (0·87-1·12) in those aged 85 years and older (adjusted pinteraction=0·050). Similar patterns of proportional risk reductions were observed for a 3 mm Hg reduction in diastolic blood pressure. Absolute risk reductions for major cardiovascular events varied by age and were larger in older groups (adjusted pinteraction=0·024). We did not find evidence for any clinically meaningful heterogeneity of relative treatment effects across different baseline blood pressure categories in any age group. INTERPRETATION: Pharmacological blood pressure reduction is effective into old age, with no evidence that relative risk reductions for prevention of major cardiovascular events vary by systolic or diastolic blood pressure levels at randomisation, down to less than 120/70 mm Hg. Pharmacological blood pressure reduction should, therefore, be considered an important treatment option regardless of age, with the removal of age-related blood-pressure thresholds from international guidelines. FUNDING: British Heart Foundation, National Institute of Health Research Oxford Biomedical Research Centre, Oxford Martin School.
引用
- Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet. 2021. PMID: 34461040. doi:10.1016/S0140-6736(21)01921-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。